Hepatic arterial infusion enhances DOTATOC radiopeptide therapy in patients with neuroendocrine liver metastases

Endocrine-Related Cancer

Volumn 18, Issue 5, 2011, Pages 595-602

  Kratochwil, Clemens ^a   López Benítez, Ruben ^a   Mier, Walter ^a   Haufe, Sabine ^a   Isermann, Berend ^a   Kauczor, Hans Ulrich ^a   Choyke, Peter L ^b   Haberkorn, Uwe ^a   Giesel, Frederik L ^a  

^a UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^b NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHROMOGRANIN A; GALLIUM 68; INDIUM 111; LUTETIUM 177; OCTREOTIDE[3 TYROSINE]; TUMOR MARKER; YTTRIUM 90;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; FEMALE; FOLLOW UP; HEPATIC ARTERY; HETERONUCLEAR NUCLEAR MAGNETIC RESONANCE; HUMAN; LIVER METASTASIS; MALE; NEUROENDOCRINE TUMOR; NUCLEAR MAGNETIC RESONANCE IMAGING; PILOT STUDY; POSITRON EMISSION TOMOGRAPHY; REMISSION; TUMOR GROWTH;

ADULT; AGED; CHROMOGRANIN A; FEMALE; HEPATIC ARTERY; HUMANS; INFUSIONS, INTRA-ARTERIAL; LIVER NEOPLASMS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; NEUROENDOCRINE TUMORS; OCTREOTIDE; PANCREATIC NEOPLASMS; PILOT PROJECTS; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; TOMOGRAPHY, X-RAY COMPUTED; YTTRIUM RADIOISOTOPES;

EID: 80054887297     PISSN: 13510088     EISSN: 14796821     Source Type: Journal    
DOI: 10.1530/ERC-11-0144     Document Type: Article

References (18)

1. 177Lu-DOTATATE: the role of associated risk factors. European Journal of Nuclear Medicine and Molecular Imaging 35 1847-1856. (doi:10.1007/s00259- 008-0778-1)
2. Bodei L, Pepe G & Paganelli G 2010 Peptide receptor radionuclide therapy (PRRT) of neuroendocrine tumors with somatostatin analogues. European Review for Medical and Pharmacological Sciences 14 347-351.
3. Jagoda EM, Vaquero JJ, Seidel J, Green MV & Eckelman WC 2004 Experiment assessment of mass effects in the rat: implications for small animal PET imaging. Nuclear Medicine and Biology 31 771-779. (doi:10.1016/j.nucmedbio. 2004.04.003)
4. de Jong M, Breeman WA, Bernard BF, van Gameren A, de Bruin E, Bakker WH, van der Pluijm ME, Visser TJ, Mäcke HR & Krenning EP 1999 Tumour uptake of the radiolabelled somatostatin analogue (DOTA0, TYR3) octreotide is dependent on the peptide amount. European Journal of Nuclear Medicine 26 693-698. (doi:10.1007/s002590050439)
5. 90Y- labeled somatostatin analogs. Journal of Nuclear Medicine 46 13S-17S.
6. 68Ga-DOTATOC PET/CT in patients with gastroenteropancreatic neuroendocrine tumors. Clinical Cancer Research 16 2899-2905. (doi:10.1158/1078-0432.CCR-10-0004)
7. 177Lu-DOTA0, Tyr3] octreotate: toxicity, efficacy, and survival. Journal of Clinical Oncology 26 2124-2130. (doi:10.1200/JCO.2007.15.2553)
8. Modlin IM, Latich I, Kidd M, Zikusoka M & Eick G 2006 Therapeutic options for gastrointestinal carcinoids. Clinical Gastroenterology and Hepatology 4 526-547. (doi:10.1016/j.cgh.2005.12.008)
9. Müller C, Forrer F, Bernard BF, Melis M, Konijnenberg M, Krenning EP & de Jong M 2007 Diagnostic versus therapeutic doses of ((177)Lu-DOTA-Tyr(3))-octreotate: uptake and dosimetry in somatostatin receptor-positive tumors and normal organs. Cancer Biotherapy & Radiopharmaceuticals 22 151-159. (doi:10.1089/cbr.2007.309)
10. Pauwels S, Barone R, Walrand S, Borson-Chazot F, Valkema R, Kvols LK, Krenning EP & Jamar F 2005 Practical dosimetry of peptide receptor radionuclide therapy with (90)Y-labeled somatostatin analogs. Journal of Nuclear Medicine 46 92S-98S. (Pubitemid 47619024)
11. Pfeifer AK, Gregersen T, Grønbæk H, Hansen CP, Müller-Brand J, Herskind Bruun K, Krogh K, Kjær A & Knigge U 2011 Peptide receptor radionuclide therapy with Y-DOTATOC and (177)Lu-DOTATOC in advanced neuroendocrine tumors: results from a Danish cohort treated in Switzerland. Neuroendocrinology 93 189-196. (doi:10.1159/000324096)
12. Raymond E, Dahan L, Raoul JL, Bang YJ, Borbath I, Lombard-Bohas C, Valle J, Metrakos P, Smith D, Vinik A et al. 2011 Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. New England Journal of Medicine 364 501-513. (doi:10.1056/NEJMoa1003825)
13. Rinke A, Müller HH, Schade-Brittinger C, Klose KJ, Barth P, Wied M, Mayer C, Aminossadati B, Pape UF, Bläker M et al. 2009 Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group. Journal of Clinical Oncology 27 4656-4663. (doi:10.1200/JCO.2009.22.8510)
14. Rolleman EJ, Valkema R, de Jong M, Kooij PP & Krenning EP 2003 Safe and effective inhibition of renal uptake of radiolabelled octreotide by a combination of lysine and arginine. European Journal of Nuclear Medicine and Molecular Imaging 30 9-15. (doi:10.1007/s00259-002-0982-3)
15. Stoeltzing O, Loss M, Huber E, Gross V, Eilles C, Mueller-Brand J & Schlitt HJ 2010 Staged surgery with neoadjuvant 90Y-DOTATOC therapy for down-sizing synchronous bilobular hepatic metastases from a neuroendocrine pancreatic tumor. Langenbeck's Archives of Surgery 395 185-192. (doi:10.1007/s00423-009-0520-x)
16. Strosberg JR, Fine RL, Choi J, Nasir A, Coppola D, Chen DT, Helm J & Kvols L 2011 First-line chemotherapy with capecitabine and temozolomide in patients with metastatic pancreatic endocrine carcinomas. Cancer 117 268-275. (doi:10.1002/cncr.25425)
17. 68Ga]-DOTATOC to somatostatin receptors in neuroendocrine tumours-impact of peptide mass. Nuclear Medicine and Biology 37 265-275. (doi:10.1016/j.nucmedbio.2009.11.008)
18. Yao JC, Shah MH, Ito T, Bohas CL, Wolin EM, Van Cutsem E, Hobday TJ, Okusaka T, Capdevila J, de Vries EG et al. 2011 Everolimus for advanced pancreatic neuroendocrine tumors. New England Journal of Medicine 364 514-523. (doi:10.1056/NEJMoa1009290)